FTH
Faeth Therapeutics, Inc.
Set alert
- YTD
- +75.16%
- 1 year
- +97.78%
- Open
- 18.56
- Prev close
- 18.75
- Mkt cap
- 482.96M
- Vol
- 510.97K
- Avg vol
- 370.25K
- EPS
- -60.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.88
- High
- 19.04
- Forward P/E
- -7.88
- Beta
- -0.28
- Short ratio
- 3.64
- Inst. own
- 78.84%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 13, 2026
- 50-d avg
- 30.99
- 200-d avg
- 22.28
- 1y target
- 54.64
News
3 days ago businesswire.com
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
-
3 days ago benzinga.com
BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target
BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.
1 week ago businesswire.com
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
1 week ago businesswire.com
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an…
1 week ago businesswire.com
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
1 week ago defenseworld.net
Sensei Biotherapeutics (NASDAQ:FTH) Shares Gap Up – Here’s What Happened
Sensei Biotherapeutics, Inc. (NASDAQ: FTH - Get Free Report)'s share price gapped up prior to trading on Friday. The stock had previously closed at $20.00, but opened at $21.00. Sensei…
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating.
1 month ago gurufocus.com
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition o
1 month ago businesswire.com
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of…
-
1 month ago benzinga.com
Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.
-
1 month ago benzinga.com
LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.
1 month ago businesswire.com
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
1 month ago zacks.com
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
1 month ago gurufocus.com
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
[url="]Faeth Therapeutics[/url] (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program
1 month ago businesswire.com
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
2 months ago businesswire.com
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an…
2 months ago zacks.com
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know
The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
2 months ago benzinga.com
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
-
2 months ago benzinga.com
Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56
Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.
-
2 months ago benzinga.com
Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer
— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors…
2 months ago businesswire.com
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
2 months ago businesswire.com
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
2 months ago businesswire.com
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted two new employees options to purchase an…
2 months ago gurufocus.com
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pa
-
2 months ago benzinga.com
Faeth Therapeutics To Present Translational Data And Pharmacokinetic/Pharmacodynamic Analysis For PIKTOR, Oral Combination Of Serabelisib And Sapanisertib, At 2026 Summit For STOP Cancer
— The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8— These data collectively informed PIKTOR dose selection in…
2 months ago businesswire.com
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway,…
-
2 months ago benzinga.com
Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate
Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.29) by 13.68 percent. This is a 27.37 percent increase over losses of…
2 months ago businesswire.com
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway,…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
3 months ago benzinga.com
This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
3 months ago benzinga.com
This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, initiations. See other analysts' views on HTFL, SKYH, FTH.
3 months ago benzinga.com
This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.
-
3 months ago benzinga.com
Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56
Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.
3 months ago benzinga.com
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.
-
3 months ago benzinga.com
Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60
Oppenheimer analyst Jay Olson initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $60.
-
3 months ago benzinga.com
Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51
Citizens analyst Silvan Turkcan initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Market Outperform rating and announces Price Target of $51.
-
3 months ago benzinga.com
BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target
BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.
4 months ago benzinga.com
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top analysts changed outlook on top names. For all changes, see analyst ratings page. See how analysts view HOOD, FXNC, NU, FTH, FRST.
-
4 months ago benzinga.com
Baird Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $57
Baird analyst Jack Allen initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $57.
4 months ago benzinga.com
This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See what analysts think of these stocks.
4 months ago benzinga.com
This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
Top Wall Street analysts changed outlook on top names. Piper Sandler upgraded SNPS, JP Morgan upgraded IBM,. See analyst ratings.
4 months ago benzinga.com
Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday
Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal with CoreWeave Inc. Other stocks also gained.
4 months ago benzinga.com
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.
4 months ago benzinga.com
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
4 months ago benzinga.com
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what analysts say about buying CRDO stock.
-
4 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $60
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $60.